CTWM
REGN icon

Cherry Tree Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cherry Tree Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$1.13K – 628
2025
Q3 		$1.13K Hold
2
– – ﹤0.01% 538
2025
Q2 		$1.05K Hold
2
– – ﹤0.01% 551
2025
Q1 		$1.27K Hold
2
– – ﹤0.01% 668
2024
Q4 		$1.43K Hold
2
– – ﹤0.01% 556
2024
Q3 		$2.1K Hold
2
– – ﹤0.01% 532
2024
Q2 		$2.1K Hold
2
– – ﹤0.01% 515
2024
Q1 		$1.93K Hold
2
– – ﹤0.01% 512
2023
Q4 		$1.76K Hold
2
– – ﹤0.01% 515
2023
Q3 		$1.65K Hold
2
– – ﹤0.01% 495
2023
Q2 		$1.44K Buy
+2
New +$1.54K ﹤0.01% 515

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cherry Tree Wealth Management's REGN Position: Q4 2025 in Review

Cherry Tree Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 2 shares — an estimated $1.13K sold.

Cherry Tree Wealth Management first reported a position in REGN in Q2 2023 and held it in 10 quarters. The position peaked at $2.1K in Q3 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Cherry Tree Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Cherry Tree Wealth Management sold 2 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $1.13K.
  • Cherry Tree Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • Cherry Tree Wealth Management's Regeneron Pharmaceuticals position peaked at $2.1K in Q3 2024.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Cherry Tree Wealth Management's 13F filing for Q4 2025, filed 10 Feb 2026.